Navigation Links
Scientists from Granada find a potential treatment to prevent diabetes and obesity
Date:10/17/2008

This press release is available in French and Spanish.

A molecule called interleukin-6 has opened new doors for the creation of new drugs against obesity and diabetes. These are the conclusions of an international project which has had the participation of researchers from Vitagenes, a company which forms part of the Campus program promoted by the University of Granada (UGR) and situated in the Technological Park of Health Sciences (PTS).

Vitagenes has collaborated in this project through its technical director, doctor Jos Luis Mesa, who has been one of the main authors of the study together with distinguished scientists of the University of Melbourne and the Baker Heart Research Institute (Australia). The most relevant results of the project, such as a potential treatment to prevent diabetes and obesity, have been published in the international scientific Journal of Endocrinology.

An (un)known molecule

The main discovery has been the change of the paradigm of a molecule called interleukin-6 in the prevention of obesity and diabetes. Up to now, scientific evidence suggested that interleukin-6, chronically high in obese persons and diabetics, could be harmful for obesity and diabetes; however, this study proves exactly the opposite. "No study had tried to inject interleukin-6 directly to analyse if this molecule was really harmful or, to the contrary, could help to prevent obesity and diabetes" Jos Luis Mesa points out. He explains that "our hypothesis was that interleukin-6 was naturally high in diabetic and obese persons precisely to combat such diseases. In order to prove it, we injected human recombinant interleukin-6 daily for two weeks and analysed its behaviour and its effects on the metabolism".

Mark Febbraio, scientific director in the Baker Heart Research Institute and a member of the Advisory Scientific Committee of Vitagenes, points out that "we obtained surprising results. The exogenous administration of interleukin-6 improved insulin sensitivity and the absorption of glucose, essential for diabetics". In addition, according to Mesa, "interleukin-6 also increased the expression of important genes related to fats metabolism, such as PPAR and UCP2. This suggests that interleukin-6 could be involved in the metabolic control of body weight".

However, Vitagenes has also reported that this is a preliminary study carried out in animal models, and we need new studies in humans to establish definite conclusions, "although everything seems to indicate that the application in humans would be possible in the medium term. This could substantially improve the state of people with diabetes and obesity", points out Mesa.


'/>"/>

Contact: Jos Luis Mesa
jose.mesa@vitagenes.com
34-678-222-210
Universidad de Granada
Source:Eurekalert

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 22, 2017 Good Start Genetics, a leading ... the 130 million covered lives mark through its most ... Texas . With newly signed contracts nationally ... enjoy strong payor acceptance based on the quality of ... genetic counseling, its industry-leading customer care and support and ...
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
(Date:3/22/2017)... March 22, 2017   Boston Biomedical , an ... designed to target cancer stemness pathways, today announced its ... as Chief Executive Officer, effective April 24, 2017. ... J. Li , M.D., FACP, who has led Boston ... Under his leadership, Boston Biomedical has grown from a ...
(Date:3/22/2017)... ... 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the ... “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ ... and Therapy Act, Okyanos maintains a mission to help “no-option” patients and those ...
Breaking Biology Technology: